In conclusion, the costs under the Medicare Part D program of aromatase inhibitors, the most effective breast cancer adjuvant endocrine agents, rose dramatically between 2006 and 2010, and then fell with the availability of generic AI agents in 2011. The gene discussed is CYP19A1; the disease is breast cancer.